Vnitr Lek 2000, 46(11):768-775

[Damage of left ventricular function after treatment with doxorubicin in patients with malignant lymphomas].

L Elbl, V Chaloupka, I Vásová, S Nehyba, J Vorlícek, M Navrátil, I Kiss, M Cíhalová
Oddelení funkcního vysetrování FN Brno.

The authors evaluated using clinical and echocardiographic examination the effect of chemotherapy involving bolus administration of doxorubicin on the heart muscle in 90 patients with non-Hodgkin lymphoma and with Hodgkin lymphoma. In 18% of patients they found an asymptomatic decrease of the left ventricular ejection fraction during chemotherapy, chronic cardiotoxicity was recorded in 5% patients, in 2% of the patients one year after termination of chemotherapy a clinically latent myocardial infarction was found. The diastolic function was impaired (impaired relaxation) in 44% patients after terminated chemotherapy and in 50% after one year. Echocardiographic examination provided evidence that the impaired systolic and diastolic function persists even after one year following termination of chemotherapy. High-dose chemotherapy with administration of peripheral stem cells did not lead to marked deterioration of left ventricular function as compared with patients who did not undergo this treatment. The main clinical complications--death, cardiotoxicity, relapse of the malignant disease, cardiovascular complications--were present in the course of a 18.5-month follow up after establishment of the diagnosis in 32% of the patients.

Keywords: Adolescent; Adult; Aged; Antibiotics, Antineoplastic, adverse effects, ; Doxorubicin, adverse effects, ; Echocardiography; Female; Heart, drug effects, ; Humans; Lymphoma, drug therapy, ; Male; Middle Aged; Risk Factors; Ventricular Dysfunction, Left, chemically induced,

Published: November 1, 2000  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Elbl L, Chaloupka V, Vásová I, Nehyba S, Vorlícek J, Navrátil M, et al.. [Damage of left ventricular function after treatment with doxorubicin in patients with malignant lymphomas]. Vnitr Lek. 2000;46(11):768-775.
Download citation




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.